Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
Clinical trial NCT03145181 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03145181
- Sponsor
- Janssen Research & Development, LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-05-16
- Primary completion
- 2025-09-25
- Enrollment
- 302
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.